Clinicopathological characteristics of the carcinomas with equivocal (2+) HER2 immunostaining
| Variable* | n | % | |
| Age (years) | N=345 | ||
| <50 | 57 | 16.5 | |
| ≥50 | 288 | 83.5 | |
| Size (mm) | N=278 | ||
| ≤20 | 143 | 51.4 | |
| >20 | 135 | 48.6 | |
| Histological type | N=345 | ||
| Ductal | 302 | 87.5 | |
| Lobular | 38 | 11.0 | |
| Others (tubular, medullary) | 5 | 1.4 | |
| Histological grade (BRE) | N=323 | ||
| 1 | 43 | 13.3 | |
| 2 | 201 | 62.2 | |
| 3 | 79 | 24.5 | |
| Oestrogen receptor | N=344 | ||
| Positive (>10% of tumour cells) | 299 | 86.9 | |
| Negative (<10% of tumour cells) | 45 | 13.1 | |
| Progesterone receptor | N=344 | ||
| Positive (>10% of tumour cells) | 241 | 70.1 | |
| Negative (<10% of tumour cells) | 103 | 29.9 | |
| Ki-67 | N=225 | ||
| Low (<20% of tumour cells) | 122 | 54.2 | |
| High (>20% of tumour cells) | 103 | 45.8 | |
| pT stage | N=278 | ||
| pT1 | 143 | 51.4 | |
| pT2 | 122 | 43.9 | |
| pT3 | 11 | 4.0 | |
| pT4 | 2 | 0.7 | |
| Nodal status | N=264 | ||
| pN− | 136 | 51.5 | |
| pN+ | 128 | 48.5 |
↵* For a subset of carcinomas, not all clinicopathological characteristics were available. BRE score, Bloom–Richardson–Elston score.